AstraZeneca plc (GB:AZN) has released an update.
AstraZeneca has announced the successful completion of a strategic equity investment in Cellectis, a biotech firm specializing in gene editing. This partnership aims to develop up to 10 new cell and gene therapies for diseases with significant treatment gaps, including in oncology and rare diseases. The deal includes a $105 million initial payment to Cellectis, followed by an additional $140 million investment, bringing AstraZeneca’s total equity stake to approximately 44%.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
